Results 1 to 10 of about 681,456 (227)
Pharmaceuticals, 2020 Drug budget and prescription control measures are implemented regionally in Germany, meaning that the uptake of pharmaceuticals, including biosimilars, can vary by region.
Evelien Moorkens +8 more
doaj +2 more sources
Exploring Stakeholder Perceptions and Experience of Biosimilar Insulin Switching: A Scoping Review [PDF]
Endocrinology, Diabetes & MetabolismBackground The option to switch patients to more cost‐effective biosimilar insulins has been available since 2014, and the market share for these medicines has been slowly increasing since then. This scoping review aimed to identify the current knowledge
Ben Hindley +4 more
doaj +2 more sources
Pharmaceuticals, 2021 Slow uptake of biosimilars in some regions is often attributed to a lack of knowledge combined with concerns about safety and efficacy. To alleviate physician and patient apprehensions, regulatory reviews from four major regulatory authorities (RAs ...
Beverly Ingram +3 more
doaj +2 more sources
Indian Journal of Ophthalmology, 2021 Purpose: The aim of this study was to evaluate the efficacy and safety of Razumab (the biosimilar Ranibizumab by Intas Pharmaceuticals Ltd.) for the treatment of chorioretinal vascular diseases such as diabetic macular edema (DME), choroidal neovascular ...
Lalit Verma +5 more
doaj +2 more sources
Clinical evidence and implementation guidance for biosimilar switching in ankylosing spondylitis [PDF]
Frontiers in PharmacologyBiosimilar tumor necrosis factor inhibitors provide therapeutically equivalent alternatives to reference biologics for ankylosing spondylitis (AS) management at reduced costs.
Luoyang Cai +6 more
doaj +2 more sources
Analytical similarity as the primary determinant of monoclonal antibody development: toward evidence-efficient regulatory frameworks [PDF]
Frontiers in Drug DeliveryMonoclonal antibodies (mAbs) constitute the most rapidly expanding and therapeutically impactful class of biological medicines, driven by their exceptional target specificity, modular engineering capabilities, predictable pharmacokinetics facilitated by ...
Sarfaraz K. Niazi
doaj +2 more sources
Frontiers in Public HealthIntroductionWhile biosimilar medicines can contribute to the sustainability of healthcare systems, their utilization rate varies across European countries.
Ferreira Pedro Lopes
exaly +3 more sources
Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients. [PDF]
Clin Pharmacol TherIn Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Iacono A +10 more
europepmc +2 more sources
Expected Impact of Biosimilars on the Pharmaceutical Companies.
Iranian journal of medical sciences, 2021 In the last three decades, biological products have gradually developed to be an essential basis in the pharmaceutical industry. Advancements in this field have encouraged the frontiers of science to bring life-saving treatments to patients suffering from incurable diseases, such as cancers and has also assisted clinicians in managing chronic diseases ...
Golshani, Shiva, Faramarzi, Mohammad Ali
openaire +3 more sources
Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure [PDF]
Frontiers in Pharmacology, 2021 Introduction: Biosimilar medicines are considered promising alternatives to new biologicals with high price tags. The extent of savings resulting from biosimilar use depends on their price and uptake, which are largely shaped by pricing, reimbursement, and demand-side policies.
Vogler, Sabine +4 more
openaire +4 more sources